Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-Of-Concept Phase 1b/2a Randomized, Vehicle, and Comparator-Controlled Study of Topical DLQ01 to Assess the Safety and Efficacy in the Treatment of Androgenetic Alopecia (AGA) in Men

NCT05636904 is registered in ClinicalTrials.gov with Dermaliq Therapeutics, Inc. as lead sponsor.

NCT NCT05636904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05636904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-Of-Concept Phase 1b/2a Randomized, Vehicle, and Comparator-Controlled Study of Topical DLQ01 to Assess the Safety and Efficacy in the Treatment of Androgenetic Alopecia (AGA) in Men
Lead sponsor
Dermaliq Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
December 5, 2022
Completion date
March 28, 2024
Enrollment
120 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

androgenetic alopecia